Complete Molecular and Hematologic Response in Adult Patients with Relapsed/Refractory (R/R) Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia (ALL) Following Treatment with Blinatumomab: Results from a Phase 2 Single-Arm, Multicenter Study (ALCANTARA)

@inproceedings{Martinelli2015CompleteMA,
  title={Complete Molecular and Hematologic Response in Adult Patients with Relapsed/Refractory (R/R) Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia (ALL) Following Treatment with Blinatumomab: Results from a Phase 2 Single-Arm, Multicenter Study (ALCANTARA)},
  author={Giovanni Martinelli and Herv{\'e} Dombret and Patrice Chevallier and Oliver G Ottmann and Nicola Goekbuget and Max S. Topp and Adele K. Fielding and Lulu Ren Sterling and Jonathan Benjamin and Anthony Stein},
  year={2015}
}
Introduction. Prognosis of patients (pts) with R/R Philadelphia chromosome-positive (Ph+) ALL is dismal despite the introduction of tyrosine kinase inhibitors (TKI) which may be used as single agents or in combination regimens. Blinatumomab is a bispecific T-cell engaging (BiTE ® ) antibody construct that has shown antileukemic activity. Among adults with R/R Ph-negative ALL receiving blinatumomab, 43% achieved complete remission (CR) or CR with partial hematologic recovery (CRh) during the… CONTINUE READING

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 22 CITATIONS

A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia.

  • Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
  • 2018
VIEW 10 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Immuntherapie von akuten Leukämien

  • InFo Onkologie
  • 2017
VIEW 7 EXCERPTS
HIGHLY INFLUENCED

Successful reintroduction of blinatumomab in a patient with relapsed/refractory acute lymphoblastic leukemia following grade 4 cytokine release syndrome.

  • Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
  • 2018
VIEW 2 EXCERPTS
CITES RESULTS